detect skin cancer with confidence

Background to Skin Cancer

The American Institute of Cancer Research indicates that one in five people will be diagnosed with skin cancer in their lifetime. There is a need for innovations to allow early detection of skin cancer. For stage I and II of melanoma skin cancer the 5 years relative survival rate is around 98%, whereas for stage IV it is only around 23%. That is why early detection is vital to saving people lives. View Derma responds to this challenge and is developing an innovative low cost, non-invasive skin cancer detection device for dermatologists and in the future for general practitioners.

The use of multi-spectral imaging allows a dermatologist to see more than the naked eye and more than the dermatoscope.  View Derma is able to visualise the ABCD characteristics with strong focus on suspected lesion pigmentation with the surrounded blood supplies in the skin, which is vital information in detecting skin cancer. Additionally, View Derma has a unique deep learning algorithm to support the specialist to make more informed, confident and accurate decisions to detect skin cancer. Nobleo and Engineering are responsible for developing the technology. UPMC-I is conducting the clinical trials in their Italian hospitals. Dermal Choices is the business Champion and will commercialize the device. 

Deepen your view

View Derma - see more, detect better

View Derma is an EIT Digital consortium consisting of UPMC-I, Nobleo, Engineering and Dermal Choices. View Derma is developing an innovative skin cancer detection device that uses multi-spectral imaging technology to assess suspicious lesions of the skin.

The use of multi-spectral imaging allows a dermatologist to see more than the naked eye and more than the dermatoscope. Additionally, View Derma has a unique deep learning algorithm to support the specialist to make more informed, confident and accurate decisions to assess the skin lesion and detect skin cancer. Nobleo and Engineering are responsible for developing the technology. UPMC-I is conducting the clinical trials in their Italian hospitals. Dermal Choices is the business Champion and will commercialize the device.

View Derma believes that this device will go a long way towards early detection of skin cancer and minimizing the catastrophic impact on people’s lives and healthcare costs of the late diagnosis.

PARTNERS

Contact us

Magdalena Scheijgrond MSc
CEO of Dermal Choices
info@dermalchoices.nl

High Tech Campus 31
5656 AE Eindhoven
The Netherlands

  • This field is for validation purposes and should be left unchanged.

This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2020 research and innovation programme.